Results of the treatment with high-dose chemotherapy followed by stem cell transplantation
| Study type . | Reference . | No. transplanted . | No. evaluable . | Debulking chemotherapy . | Conditioning treatment . | Complete response . | Median survival, mo (range) . |
|---|---|---|---|---|---|---|---|
| Retrospective | 16 | 2 | 2 | PEACE-BOM | BEAM | 2 | 31 (2-64) |
| Retrospective | 69 | 1 | 1 | EPOCH-ICE | MPH-FARA | 1 | 11 |
| Retrospective | 72 | 2 | 2 | CHOP, MACOP-B | BEAM, BEAM-like | NG | NG |
| Retrospective | 70 | 1 | 1 | CHOP-ESHAP | MCVC | 0 | 8 |
| Retrospective | 66 | 6 | 6 | IVE-HDMTX | BEAM | 5 | 40 (3-52) |
| Retrospective | 71 | 1 | 1 | CHOP | BEAM | 1 | 18 |
| Retrospective | 68 | 4 | 4 | CHOP | BEAM or MPH-FARA | 1 | 8 (2-34) |
| Retrospective | 65 | 5 | 5 | CHOP | BEAM, BEAM-like | NG | 2 (0.5-14) |
| Retrospective | 74 | 1 | 1 | CHOP | BEAM | 1 | 24 |
| Retrospective | 73 | 2 | 0 | PACEB-IVAM-HAM | BEAM | 1 | NG |
| Prospective | 67 | 5 | 0 | CHOP + DACMEMP (or PAEM) | TBI + HDCTX | NG | NG |
| Prospective | 64 | 14 | 14 | CHOP-IVE/MTX | TBI + HDMPH or BEAM | 10 | 60% at 5 y |
| (1-140+) | |||||||
| Prospective | 75 (RCD) | 13 | 13 | MPH-FARA | 5 | 66% at 4 y | |
| (10-67) |
| Study type . | Reference . | No. transplanted . | No. evaluable . | Debulking chemotherapy . | Conditioning treatment . | Complete response . | Median survival, mo (range) . |
|---|---|---|---|---|---|---|---|
| Retrospective | 16 | 2 | 2 | PEACE-BOM | BEAM | 2 | 31 (2-64) |
| Retrospective | 69 | 1 | 1 | EPOCH-ICE | MPH-FARA | 1 | 11 |
| Retrospective | 72 | 2 | 2 | CHOP, MACOP-B | BEAM, BEAM-like | NG | NG |
| Retrospective | 70 | 1 | 1 | CHOP-ESHAP | MCVC | 0 | 8 |
| Retrospective | 66 | 6 | 6 | IVE-HDMTX | BEAM | 5 | 40 (3-52) |
| Retrospective | 71 | 1 | 1 | CHOP | BEAM | 1 | 18 |
| Retrospective | 68 | 4 | 4 | CHOP | BEAM or MPH-FARA | 1 | 8 (2-34) |
| Retrospective | 65 | 5 | 5 | CHOP | BEAM, BEAM-like | NG | 2 (0.5-14) |
| Retrospective | 74 | 1 | 1 | CHOP | BEAM | 1 | 24 |
| Retrospective | 73 | 2 | 0 | PACEB-IVAM-HAM | BEAM | 1 | NG |
| Prospective | 67 | 5 | 0 | CHOP + DACMEMP (or PAEM) | TBI + HDCTX | NG | NG |
| Prospective | 64 | 14 | 14 | CHOP-IVE/MTX | TBI + HDMPH or BEAM | 10 | 60% at 5 y |
| (1-140+) | |||||||
| Prospective | 75 (RCD) | 13 | 13 | MPH-FARA | 5 | 66% at 4 y | |
| (10-67) |
EPOCH-ICE indicates etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, ifosfamide, carboplatin, and etoposide; MPH-FARA, melphalan and fludarabine; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin; NG, not given; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin; MCVC, ranimustine, carboplatin, etoposide, and cyclophosphamide; IVE-HDMTX, ifosfamide, etoposide, epirubicin, and high-dose methotrexate; PACEB, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine, and prednisone; IVAM, ifosfamide, etoposide, cytosine arabinoside, and methotrexate; HAM, cytarabine and mitoxantrone; DACMEMP, dexamethasone, cytarabine, carmustine, etoposide, methylprednisolone, and cisplatin; PAEM, cisplatin, cytarabine, etoposide, and methylprednisolone; TBI, total body irradiation; HDCTX, high-dose cyclophosphamide; and HDMPH, high-dose melphalan.